ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,664 | +205.9% | 79,849 | +251.3% | 0.14% | +164.8% |
| Q2 2023 | $544 | -99.9% | 22,730 | -25.3% | 0.05% | -15.6% |
| Q2 2022 | $429,000 | -62.2% | 30,447 | -55.4% | 0.06% | -44.8% |
| Q3 2021 | $1,135,000 | +179.6% | 68,330 | +620.3% | 0.12% | +146.8% |
| Q4 2019 | $406,000 | +6.0% | 9,486 | -10.8% | 0.05% | -9.6% |
| Q3 2019 | $383,000 | +57.6% | 10,638 | -9.2% | 0.05% | +300.0% |
| Q3 2018 | $243,000 | -30.0% | 11,717 | +20.4% | 0.01% | -23.5% |
| Q4 2015 | $347,000 | -69.8% | 9,731 | -72.0% | 0.02% | -69.6% |
| Q3 2015 | $1,148,000 | -34.8% | 34,708 | -17.5% | 0.06% | -17.6% |
| Q2 2015 | $1,762,000 | -22.0% | 42,077 | -39.3% | 0.07% | -24.4% |
| Q1 2015 | $2,258,000 | +532.5% | 69,295 | +516.9% | 0.09% | +260.0% |
| Q4 2014 | $357,000 | -40.7% | 11,233 | -54.6% | 0.02% | -41.9% |
| Q1 2014 | $602,000 | – | 24,751 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |